News

Partnership model gives physicians better tools for insulin therapy and offers new reimbursement opportunities Livonia, Michigan, Jan. 10, 2023 — Hygieia, a provider of digital therapeutics for insulin management, has added Endocrinology Associates, PA, in Scottsdale and Chandler, AZ, as a clinical partner. This makes Hygieia’s d-Nav® autonomous insulin therapy service available to patients with type…

Demand grows for d-Nav Technology, the first FDA-cleared app to autonomously adjust insulin doses Livonia, Michigan, Dec. 13, 2022 — Hygieia, a digital therapeutics company, has relocated and expanded its headquarters to accommodate additional staff as it continues significant growth and pursues partnerships with endocrinology practices across the United States. Hygieia’s expansion is in response to increased…

Partnership model increases doctors’ ability to coordinate patients’ insulin therapy andoffers new reimbursement opportunities Livonia, Mich., Sept. 12, 2022 — Hygieia, a provider of digital therapeutics for insulin management, has added Endocrine Associates of West Village P.C. in Manhattan and Long Island City, NY, and Physicians East in Greenville, NC, as clinical partners. The partnerships are…

New partnership expands availability of d-Nav program for underserved Livonia, Mich., August 30, 2022 — Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner. The partnership extends Hygieia’s d-Nav® network and makes autonomous insulin therapy service available for an underserved population. The unique…

Livonia, Michigan, Aug. 23, 2022 – Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav® Insulin Management Program. Lawrence brings three decades of medical technology leadership to his new role at Hygieia, including significant experience…

Livonia, Mich., July 26, 2022 – Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III codes for autonomous insulin dose titration, which can be used for Hygieia’s d-Nav® Technology. d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations…

Livonia, Michigan, June 23, 2022 – Hygieia, a digital therapeutics company for insulin therapy, has successfully licensed its d-Nav insulin management technology to Movement Group, a provider of health and wellness programs to integrated health delivery networks in Israel. The agreement is part of an accelerated strategy to expand its d-Nav insulin titration technology globally. d-Nav…

SAN DIEGO, Calif.–(BUSINESS WIRE)–Hygieia, a digital therapeutics company, today announced the official launch of its d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes. The d-Nav Clinical Partnership Program is turnkey. It provides patients with access to d-Nav autonomous insulin dose technology and a clinical support team. For clinical partners, the d-Nav…

Funding will enable expansion of company’s AI-driven d-Nav® technology, which automates real-time insulin dose recommendations for people with type 2 diabetes LIVONIA, Mich., December 2, 2021 – Hygieia, a digital health company for insulin management, has closed on an initial $17 million Series B investment round, led by Israeli venture capital firm Firstime Ventures, and with participation from…